The HTA 2.0 Europe – Teaming up for Value conference was organised within the framework of the EUnetHTA Joint Action 2 (2012-2015) by AGE.NA.S (the Italian national Agency for regional health services) and the EUnetHTA Secretariat (DHMA, Danish Health and Medicines Authority). The conference gathered more than 450 participants from all over Europe, representing all sectors relevant to health; including policymakers, academia, assessors, industry, payers, patients and providers.
Today, on 30 October, the first day of HTA 2.0 Europe conference, the HTA Network Strategy and the EUnetHTA JA2 Recommendations went live. The Recommendations and the Strategy have been developed throughout 2014 in parallel processes, with both the strategic and scientific/technical levels of the European cooperation on HTA working in synergy to ensure consistency and coherence of the next steps in implementation. Both documents were formally endorsed in October 2014.
Yesterday, on 22 October, the European Parliament confirmed the 28 commissioners put forward by the president-elect of the European Commission Jean-Claude Juncker. Pharmaceutical and Medical Devices policies will remain in the health portfolio under incoming Commissioner Vytenis Andriukaitis.
How does EUnetHTA make a difference in national and regional HTA processes? Is industry seeing an evolution in interaction between HTAs and regulators? What are the EUnetHTA JA2 Recommendations (endorsed by the EUnetHTA Plenary Assembly) on sustainable European cooperation on HTA? Where are synergies between regulation, HTA, policy and reimbursement decision-making that will benefit European patients?
The European Commission has Health Technology Assessment (HTA) as a primary theme in the latest Directorate General for Health and Consumers’ (DG Sanco) Newsletter Issue no. 136 of 18 September 2014.